Although Pfizer Inc.’s COVID-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), has yet to be authorized anywhere, the push for compulsory licensing of the drug has begun.

Mitsubishi Tanabe Pharma Corp.'s Medicago Inc. plans to "imminently" seek Health Canada approval for its plant-based COVID-19 vaccine candidate, MT-2766, after top-line phase III results showed an overall vaccine efficacy rate of 71% against all variants of SARS-CoV-2.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cyprium, Enlivex, Gan & Lee, Octapharma, Roche, Sentynl, Theratechnologies, Vincerx.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aerie, Alvotech, Anixa, Arbutus, Biovaxys Technology, Cancer Advances, Clover, Coda, Delix, Gain, Galderma, Hyundai, Glaxosmithkline, Hansa, Janone, Medison, Meryx, Molgenie, Novartis, Proteros Biostructures, Recursion, Roche, Santen, Scilex, Sosei, Sorento, Spago, Specific, Syndevrx, Taysha, Vickers, Vir, Vtv, X-Chem, Xcovery, XNK.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Acurx, Aeglea, Bavarian Nordic, Biohaven, Catalyst, Citius, Cyxone, Dydo, Glycomimetics, Hutchmed, Implicit, J&J, Karyopharm, Kazia, Kronos, Mediwound, Mesoblast, Nrx, Ocular, PDS, Ventyx, Xenon, ZZ.

LONDON – New research shows the extent to which an individual’s immune response to the SARS-CoV-2 virus is affected by which variants they are initially exposed to, a finding that has consequences for attempts to update vaccines against emerging variants of concern.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Abcellera, Amicus, Amydis, Ascletis, Atamyo, Beigene, Biotheus, BMS, Cyclo, Eli Lilly, Eusa, Henlius, Jacobio, Junshi, Kolon, Legend, Longeveron, Merck & Co., Noramco, RDIF, Redhill, Roche, Sapience, Spectrum, Ultimovacs, Valneva.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abionyx, Alpha Cognition, Aqilion, Bayer, Bsense, CAMP4, Carisma, GB Biosciences, Greenlight, Gritstone, IO, Inflammasome, J&J, Julphar, Kaleido, Merck & Co., NGM, Pfizer, Phylex, Poolbeg, Pulmocide, Quantum, Rarestone, Recursion, RDIF, Rhythm, Secura, Sinovac.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagene, Adicet, Astrazeneca, Bayer, Bellicum, Biofrontera, Bolt, Eupraxia, Fulcrum, Hummingbird, I-Mab, Immunicum, Immunocore, Janssen, Merus, Neurona, Revive, Scynexis, Springworks, Stoke, Surface Oncology, Viacyte.